Compound Screening Disease Pharma Companies Treatment 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges .
Drug Discovery World
JANUARY 26, 2023
Research into HIV blossomed throughout 2022, with ViiV Healthcare’s combination therapy for HIV-1 gaining approval in Japan; and research moving forward towards a one-time treatment for HIV as well as a vaccine. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.
Expert insights. Personalized for you.
130 
Let's personalize your content